Midgard Science

Axcelead

Kanagawa, Japan axcelead-us.com

From their website, Nov 2026

Work here? Claim this listing

About

Axcelead Drug Discovery Partners, Inc. provides drug discovery and development services for biotechnology and pharmaceutical partners, with work spanning target discovery through IND enabling. It is based in Fujisawa, Kanagawa, Japan and was formed in 2017 as a Takeda spin-out.

Services

  • Integrated drug discovery

    End-to-end drug discovery services from target discovery to IND-enabling translational research.

    Assays & in vitro testing

  • Axcelead Booster

    Data-driven drug candidate generation using legacy pharma projects, proprietary data, AI tools, and discovery platforms.

  • Target identification / validation

    Supports identification of novel drug targets using human data-driven transcriptomics and proteomics, and validates targets with human samples and disease models.

    Assays & in vitro testing

  • Hit identification / characterization

    Provides HTS strategy design, assay development, hit characterization, compound library screening, and hit prioritization.

    Assays & in vitro testing

  • Lead generation / optimization

    Supports medicinal and analytical chemistry, biology, DMPK, safety evaluation, and in silico design for lead generation and optimization.

    Assays & in vitro testing

  • Candidate selection

    Evaluates optimized compounds for IND feasibility using PK/PD/E, TK/TD, modeling and simulation, human PK/effective dose prediction, and safety assessment.

    ADME, DMPK & toxicology

  • IND enabling

    Provides Smart-IND project support from candidate selection to IND filing, including strategy, project management, non-GMP bulk preparation, and modality-specific planning.

    ADME, DMPK & toxicology

  • Chemistry

    Offers medicinal, computational, synthetic, and analytical chemistry, including hit expansion, lead generation, and lead optimization.

  • Targeted protein degradation

    Supports TPD drug discovery at the preclinical stage with specialized chemistry and assay systems.

  • RNA-targeted small molecules

    Provides integrated discovery support for RNA-targeted small molecule programs at the preclinical stage.

  • Omics

    Uses omics technologies to link genes, proteins, and metabolites for biological insight.

    Assays & in vitro testing

  • Bioinformatics

    Converts omics and genomics data into actionable insights for drug discovery.

    Assays & in vitro testing

  • In Vitro/In Vivo Pharmacology

    Offers pharmacology support as part of its technology platform.

    Assays & in vitro testing

  • Genetically Modified Animal

    Uses genetically modified animal models as a technology platform.

    Assays & in vitro testing

Lead time
2–3 business days · Under 12 months · 6 months · 1 year
What to send
Diseases of interest, target classes, or specific targets · First Name · Last Name · Email · Organization / Company

Capabilities

Processes
Small molecule · Peptide · Oligonucleotide · Cell therapy · Small molecules · HTS · Peptides · Oligonucleotides · In vivo
Capacity
1.2+ million compounds · 1,000 pharma-originated legacy projects · 700+ HTS experiences · 96 parallel syntheses over 5 to 10 days · More than 50 projects for 5 years · 7 candidates · 1 IND · About 240 employees · 1.5 million compounds

Equipment

  • High throughput screening
  • GPU machines
  • 2000 CPU cluster machines

Industries served

  • Biotech
  • Pharmaceuticals
  • Academia
  • Public institutions

Company

Type
CRO
Founded
2017
Team
About 240

Locations

Based in
Kanagawa, Japan
Sites
Fujisawa, Japan · Kanagawa, Japan · Fujisawa, Kanagawa, Japan
Serves
biotechnology and pharmaceutical partners, corporate, start-up, academia, and public institutions, Japan, around the world

Similar labs

Work here? Claim this listing